SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up – What’s Next?

Posted by Brenda Bartman on Aug 12th, 2026

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) shares gapped up prior to trading on Wednesday . The stock had previously closed at $11.05, but opened at $11.92. SELLAS Life Sciences Group shares last traded at $11.7370, with a volume of 1,562,683 shares trading hands.

Analysts Set New Price Targets

Several equities analysts have recently commented on SLS shares. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, SELLAS Life Sciences Group has an average rating of “Hold” and a consensus target price of $10.00.

Get Our Latest Research Report on SLS

SELLAS Life Sciences Group Stock Performance

The company’s fifty day moving average price is $11.01 and its 200 day moving average price is $7.24. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -50.78 and a beta of 2.48.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp raised its holdings in shares of SELLAS Life Sciences Group by 86.6% during the first quarter. Bank of New York Mellon Corp now owns 478,366 shares of the company’s stock valued at $2,023,000 after buying an additional 221,957 shares during the last quarter. Dagco Inc. increased its position in SELLAS Life Sciences Group by 19.8% in the 2nd quarter. Dagco Inc. now owns 1,232,433 shares of the company’s stock valued at $18,191,000 after acquiring an additional 203,653 shares during the period. Fifth Third Bancorp bought a new stake in SELLAS Life Sciences Group during the 1st quarter valued at $253,000. World Investment Advisors acquired a new position in SELLAS Life Sciences Group during the 4th quarter worth $166,000. Finally, Millington Financial Advisors LLC acquired a new stake in shares of SELLAS Life Sciences Group in the fourth quarter valued at $93,000. 17.38% of the stock is owned by institutional investors and hedge funds.

SELLAS Life Sciences Group Company Profile

(Get Free Report)

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.